Salvage therapy before stem cell transplant for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (sonrotoclax, cladribine, and cytarabine) as a rescue treatment for people whose acute myeloid leukemia (AML) has come back or not responded to previous treatment. The goal is to prepare patients for a stem cell transplant, which may offer a chance for long-term remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has returned or not responded to earlier treatment.
- You are between 18 and 65 years old.
- You are planning to have a stem cell transplant using donor cells (from a related or unrelated donor).
- You are generally able to care for yourself (ECOG score 0-2).
- You have not had a stem cell transplant before.
- You do not have uncontrolled infections, active heart disease, or severe liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger chemotherapy regimen before a stem cell transplant to see if it can reduce the chance of leukemia coming back. It is for adults with acute myeloid leukemia who are in first remission.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
This trial tests a new way to make a treatment more effective and safer for people with acute myeloid leukemia (AML) that has returned after a stem cell transplant. The treatment modifies your own blood stem cells to remove a marker called CD33, then uses an immunotherapy that targets CD33 on cancer cells, potentially reducing side effects.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.